In order to maintain a healthy HbA1C, type 1 diabetics need to be
able to quickly,
accurately and consistently determine and track their glucose levels and predict imminent and overall
Δglucose. This can help the patient prevent hypo- and hyperglycemic events, the former of which occurs
approximately twice a week. (Lin et al., 2023) Existing market Continuous Glucose Monitoring devices
(CGMs) are able to achieve this (ADCES Staff Writer, 2024) but the medical adhesives used by them can
cause skin irritation. (Messer et al., 2018) Current generation CGMs also require peripheral devices,
such as a mobile device, and an NFC connection to display, store and share data with family members and
healthcare practitioners.
Type 1 diabetics are able to check their glucose levels through
two methods,either blood glucose,
measured manually, or interstitial fluid glucose, measured via CGM. Manual blood testing can cause
scarring on the fingers, which makes it progressively harder to test blood glucose, which leads to test
infrequency. Test infrequency leads to poorly managed glucose levels and more frequent hyper- and
hypoglycemic events, as opposed to the average of two-four events per week. Manual blood tests also
require a blood testing kit, consisting of a short spring loaded needle, an absorbent strip and blood
glucose analysis device, which means that diabetic patients need to carry these peripherals with them at
all times, which can get in the way of certain lifestyles and activities.
Type 1 diabetics are able to check their glucose levels through two methods,either blood glucose,
measured manually, or interstitial fluid glucose, measured via CGM. Manual blood testing can cause
scarring on the fingers, which makes it progressively harder to test blood glucose, which leads to test
infrequency. Test infrequency leads to poorly managed glucose levels and more frequent hyper- and
hypoglycemic events, as opposed to the average of two-four events per week. Manual blood tests also
require a blood testing kit, consisting of a short spring loaded needle, an absorbent strip and blood
glucose analysis device, which means that diabetic patients need to carry these peripherals with them at
all times, which can get in the way of certain lifestyles and activities.
This causes problems when patients need frequent data to maintain a healthy HbA1C, and a poor HbA1C can
lead to keto-acidosis, necrotic tissue in the extremities, and potentially, death.
Ideally, patients would not need any assistance to maintain an HbA1C of 6.5%

The Objectives of the project are to create a device that can act as an
implantable CGM device, that
does not need to use adhesives, and that can be continuously used without replacement. Secondary
objectives for the device would be to have hypoglycemic response Glucose injection, and an added CSII
device.
The project aims to lessen the prevalence of poor-HbA1C health complications, as well as comfortably
lower the average HbA1C to the 6-7% range, which is considered the diabetic ideal range.
The project will attempt to achieve this aim by method of the following objectives: Increase the usage
of CGM systems within the diabetic population, Increase the sampling value of the average glucose
trajectory tests in order to present clearer and more accurate results, and respond automatically to
hypoglycemic and hyperglycemic events, to increase time-in-range. To achieve these objectives, the
product needs to have an inegrated CSII and glucose injection system, be attached to the epidermis in a
way that does not irritate the skin, be easily readable to the diabetic patient, and be entirely
self-contained.
In order to fulfill the requirements as stated above, the CGM/CSII system would
have to be a wearable technology. This would have to be developed to be functional and stylish, as well
as
have a simple to use User Interface. The product was then designed as a watch/ armband combo, which
could be
interacted with by interfacing with the watch-face. The interface was then designed to fit a circular
screen, and be interacted with via touch screen gestures. The user interface was designed to use as
little
text as possible, favouring simple icons, so that the user would not struggle to read the interface
quickly.
The first step in the creating the product was generating the
3d model. This involved first sketching some designs for the product, as well as coming up with a name
for the product. At this stage, the name : "InsuGuard" was chosen, and the initial design of the watch
finalised.
Following this, work on 3d modelling began, which consisted initially low fidelity shapes, and thinking
about materials to be used in the construction of the 3d model. The main body of the watch-face and
armband would be made of a relatively cheap, yet stylish metal, and the bands or straps would be made of
a medically safe rubber or silicon material.
After selecting materials to be used for the product, the initial model was refined to include finer
details, such as the buttons on the side of the watch face. and the latches on the ends of the
watch-strap and the armband.
the next step was to create an interface for the product, so that it could be interacted with by the
user. The interface would have to be readable on a small screen, and be able to be interpreted quickly
in order to read blood glucose. With that in mind, an almost text-less interface was designed, using
symbols to indicate interactable components.
The interface was then applied to the 3d model, and a studio space was created in blender, with lights
and camera set ups. These were then animated in order to create the video content presented to clients
as a final deliverable.
This awesome website is designed to be viewed on landscape screens. Please return
to this webpage on a laptop or desktop PC.